Member Info for hangs2left

Manchester and Brighton were mentioned prior to that release so continue means others. Have faith🤑

👋Welcome Balal Hussain, our new Field Service Engineer!

His expertise will be instrumental as we continue to roll out our pharmacogenetic tests around the country.

🙂It’s great to have you on the team!

As we continue to roll out our tests around the country

Continue. And around the country 🤗

Why would Nice spend years evaluating and then recommending as POC if NHS private hospitals didn’t need them

They have better things to do

Would have been scrapped years ago if a needed product

Why after all these years of would people lose patience in the products which have only come available few weeks ago. Go figure

Game changer" rapid genetic test will save hearing of hundreds of babies annually in the UK alone

antibiotics

Occasionally the spreading news is good, and this is good: a 25-minute bedside test that will determine if newborns in need of antibiotic treatment have a gene that could result in permanent hearing loss if treatment is adminstered with the common emergency antibiotic, Gentamicin.

“Game changer” rapid genetic test will save hearing of hundreds of babies annually in the UK alone

Until now – and successful trials by the UK's National Health Service (NHS) – the process of searching for the gene possessed by one in 500 babies takes days to perform, too long to be of use because babies admitted to intensive care and needing antibiotics for infections are standardly given the antibiotic Gentamicin within 60 minutes. And then it's too late for the genetically vulnerable.

The thrill that a new test can determine in just 25 minutes whether a baby is vulnerable has been spreading throughout the medical and research community since the publication in JAMA Pediatrics on March 21 of a study showing that MT-RNR1 POCT, this great new kid on the block, meets the objective its developers had in mind at its conception: point-of-care genotyping in the acute neonatal setting to avoid aminoglycoside-induced ototoxicity without disrupting normal standards of care.

It is estimated the test could save the hearing of 180 babies in England alone every year, while also knocking £5m off the annual NHS spend by reducing the need for other interventions, such as cochlear implants. Worldwide, the impact will save the hearing of tens of thousands of babies.

Mike Hobday, Director of Policy and Campaigns at the National Deaf Children’s Society, said: “Up to now the genetic test has taken too long to return from the lab to be useful for babies requiring urgent treatment but a rapid test will be a game-changer.”

Currently around 1,260 people per annum in England have cochlear implants.

• The total number of people treated is estimated to increase to 2,790 by 2023/24.

• Of the 32,654 deaf school children in England, 2184 had implants, 7% of the total (CRIDE data).

• The cost of a cochlear implant surgery is estimated £60K per patient

Dont think Dr Ian Gilham would have purchased 1million shares 2weeks ago if bad news was around the corner. Only if good news

Would like to see more in-house purchases though

Is it time the board let out all news of sales. Orders. Too much kept back. No wonder no major shareholders have arrived after all these years

Surely Genedrive plc should give out number of devices shipped at this moment in time. Price sensitive if anyone knew the figures. ie I’d sell up if it was 15 devices but buy if I found it to be 850 devices. They are supposed to keep shareholders in the loop not just friends

Was RNS re France. Austria. Greece. Saudi Arabia. Turkey. Netherlands had placed orders

Anybody had any insight on how many Genedrive devices there are out there other than the 10 in the UK?

Surely must be made known.

Just that they manufacture in wetherby as well as Germany and Italy. Strange they can manufacture devices in wetherby stamped Genedrive

This time next week

We are pleased to announce our new partnership with Genedrive, an agreement that allows us to become the exclusive distributors in Italy for the Genedrive MT-RNR1 ID Kit.

This advanced point-of-care test marks a breakthrough in the field of rapid neonatal diagnostics, providing healthcare professionals with a reliable and efficient tool for genetic detection.

The kit is designed to deliver rapid and accurate results in time-sensitive situations, before the prescription of aminoglycoside antibiotic therapy, significantly improving clinical decision-making processes and patient safety.

As a non-invasive test the Genedrive MT-RNR1 ID Kit reduces the risk of hearing loss induced by aminoglycoside antibiotics by detecting the patient’s MT-RNR1 gene variant status.

With this partnership, we are excited to bring a new innovation to the Italian market, supporting healthcare professionals in delivering superior quality care to their patients.

Is this the manufacturer of genedrives products

Nice big buys over last few days.

Kelliop’s new RapidSeq™ system is designed to provide healthcare professionals and lay people reliable, quick qPCR results, typically ready in 15-30 minutes for people with symptoms of multiple common respiratory viral infections, such as Covid-19, Influenza A and B, RSV, and ADV to allow fast, informed triage and treatment decisions

At the time of announcement, Kelliop group has filed and obtained CE approval in Europe, and expect to file for FDA EUA approval, and Chinese NMPA approval shortly.

Kelliop expects to have production capacity to manufacture 5,000-10,000 of instruments, and millions of tests available per month for the United State, EU, China, and SEA markets in 6-12 months.

Portable instrument and small reliable disposable microfluidic cartridge are designed to be affordable and enable convenient sample-to-answer use by healthcare professionals and even untrained lay people at various point-of-care locations or in resource-limited settings.

Test is designed for use with a nasopharyngeal swab to allow quick and convenient sample collection and minimally-invasive testing experience for patients

- Kelliop (www.kelliop.com) announced today a breakthrough multiplexed qPCR system RapidSeq™ using state-of-art microfluidic lab-on-a-chip technology, for a multiple respiratory viral infection test that is designed for use by healthcare professionals in point- of-care settings with patients experiencing symptoms of respiratory infections.

The test is designed to help healthcare professionals quickly identify SARS-CoV-2, Influenze A, Influenza B, RSV, and ADV infections, typically in 15-30 minutes, in people exhibiting symptoms of respiratory infections. It uses a simple nasopharyngeal swab sample and comes in a small, convenient kit that does not require laboratory instruments, so it can be used at various point-of- care locations close to the patient and in settings where healthcare resources are limited. The test is highly beneficial where timely decisions are needed and clinical laboratory-style PCR tests are not readily available.

As the COVID-19 pandemic persists, and the emergence of new pandemic threats such as Monkeypox, and the yearly flu season approaching, it’s becoming more and more important to increase immediate testing for all patients in multiple settings, particularly at the point of care, ER, ICU, and travel gateways, said Dr. Frank Chen, CSO of Kelliop. This new rapid multiplexed qPCR test will provide a much needed solution to the healthcare system and general public, as broad access to testing will be instrumental for returning our society to normalcy, and for timely responses for future outbreaks.

Kelliop expects to have tens of millions of RapidSeq™ Respiratory qPCR Tests available per month in the United States , EU, China, and SEA markets in 6-12 months with the capacity to produce additional volumes as needed to help address pandemic testing demand. A portable instrument in the system could be m

Genedrive Ceo said in June only one competitor in America and it wasn’t Kelliop

It does say Kelliop are hoping for FDA approval later this year?

Hoping they are the out sourced manufacturer of gene drive in America Otherwise they stole genedrives technology

Valley Children’s Hospital First in U.S. to Use Advanced Genetic Testing to Save Babies’ Hearing

06.25.2024

Valley Children’s Hospital First in U.S. to Use Advanced Genetic Testing to Save Babies’ Hearing

What if a gentle swab of an infant’s cheek was all it took to know if giving them a common antibiotic could also lead to long-term hearing loss?

That is what Valley Children’s Precision Medicine Program is hoping to do: the team is the first in the nation to investigate the use of a revolutionary genetic test that may quickly let a doctor know if their tiny patient is at higher risk of hearing damage from a type of antibiotic known as an aminoglycoside. Once a doctor knows that the baby has a particular version of a key hearing gene, they can then choose a different course of care to treat an infection.

“Genes are like the individual instructions in a book that tell the body how to build and work, so understanding them is important in creating a treatment plan for each patient,” said Dr. Jeremy Woods, Valley Children’s geneticist and director of the Precision Medicine Program.

Aminoglycosides are a class of antibiotics often used to treat infections for infants in the neonatal intensive care unit (NICU). But in addition to attacking bacteria, the medicines can also attack human proteins that are vital to hearing development. That’s not usually a problem, but for babies born with certain variants of the MT-RNR1 gene, the risk for aminoglycoside-induced hearing loss (AIHL) is much greater. Insights suggest that this could be the explanation for at least 1% of hearing loss that occurs in children before language development, and likely more.

The problem until now was being able to check the baby’s genetic “map” quickly if they got sick. Valley Children’s researchers are planning to study whether this can be accomplished with a simple, non-invasive test. A small saliva sample from the baby’s cheek will be analyzed by a special machine developed by a company known as Kelliop which tests for changes in the MT-RNR1 gene. The machine is no larger than an inkjet printer and can deliver results to physicians in under an hour when time is of the essence. Valley Children’s Precision Medicine team is leading this research by conducting MT-RNR1 rapid testing for patients outside of the hospital, with plans to seek Food and Drug Administration (FDA) approval for this process in an effort to standardize this preventative care for babies at risk of hearing loss in the hospital later this year.

“Previously, we would have to wait weeks for the results of MT-RNR1 genetic testing. Now, we can have results back in under an hour,” Dr. Woods said. “That gives us plenty of time to choose a safer antibiotic to treat a seriously ill baby.”

This life-changing advancement is one of several innovative tools being pioneered by Valley Children’s Precision Medicine Program. Earlier this year, the hospital began